Pregabalin API Manufacturers & Suppliers

Pregabalin (CAS 148553-50-8) is a gamma‑aminobutyric acid analogue classified within the gamma amino acids and derivatives. It is approved for managing neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain after spinal cord injury, and as adjunctive therapy for partial‑onset seizures in patients one month of age and older. It is marketed globally under the trade names Lyrica and Lyrica CR.

Pregabalin shows no direct activity at GABA, benzodiazepine, dopamine, serotonin, opioid, or sodium channel targets. Its pharmacodynamic profile is defined by high‑affinity binding to the alpha2‑delta subunit of presynaptic voltage‑gated calcium channels in the central nervous system. This interaction reduces calcium‑dependent release of excitatory neurotransmitters such as glutamate, substance P, norepinephrine, and calcitonin gene‑related peptide. Evidence also indicates that pregabalin limits trafficking of alpha2‑delta subunits from dorsal root ganglia to the spinal dorsal horn, supporting its antinociceptive and antiseizure effects.

Pregabalin is rapidly absorbed, with bioavailability generally above 90 percent and minimal protein binding. It undergoes negligible metabolism and is eliminated largely unchanged in urine, making renal function a primary determinant of clearance. Dose adjustments are required in renal impairment, and the compound is not subject to significant CYP‑mediated interactions.

Clinical safety considerations include dizziness, somnolence, peripheral edema, and weight gain. Reports of misuse and dependence exist, with higher risk in individuals with current or past substance use disorders. Pregabalin does not bind to opioid receptors but may potentiate central nervous system depression when combined with sedatives. Rare cases of angioedema have been documented, and abrupt discontinuation may lead to withdrawal symptoms.

For API sourcing, procurement teams should verify compliance with pharmacopeial specifications, control of stereochemical purity, and robust management of residual solvents and genotoxic impurities. Consistent particle size distribution and validated controls for polymorphism are critical for formulation performance and regulatory acceptance.